Quick Answer
Inhibikase Therapeutics, Inc. reported Stockholders Equity of $172.90 million for fiscal year 2025.
Inhibikase Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $172.90M | +82.3% |
| 2024 | $94.87M | +764.2% |
| 2023 | $10.98M | -47.8% |
| 2022 | $21.04M | -45.2% |
| 2021 | $38.42M | +292.6% |
| 2020 | $9.78M | +317.9% |
| 2019 | -$4.49M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $72.90M | +13839.1% | -8.9% |
| June 30, 2025 | $80.05M | +1470.7% | -6.6% |
| March 31, 2025 | $85.73M | +1165.1% | -9.6% |
| December 31, 2024 | $94.87M | +764.2% | +17979.4% |
| September 30, 2024 | -$530.6K | -103.5% | -110.4% |
| June 30, 2024 | $5.10M | -73.8% | -24.8% |
| March 31, 2024 | $6.78M | -73.2% | -38.3% |
| December 31, 2023 | $10.98M | -47.8% | -26.9% |
- Inhibikase Therapeutics, Inc. showed an increase of +82.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Inhibikase Therapeutics, Inc.’s stockholders equity has grown by 3950.8% (from -$4.49 million to $172.90 million).
- The most recent figure is from Inhibikase Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: